Keytruda is a brand name for the drug pembrolizumab, which is a type of immunotherapy that works by helping the immune system recognize and attack cancer cells. According to the sources provided, the price of Keytruda can vary based on a number of factors, including dosage and treatment duration.
The first source, Drug Patent Watch [1], provides information on the patent status and expiration date of Keytruda. While this information is important for understanding the availability of generic versions of the drug, it does not provide any information on pricing.
The second source, Keytruda's official website [2], offers information on financial support options for patients who need help paying for the drug. The website states that the cost of Keytruda can vary depending on a patient's insurance coverage and other factors, and that the company offers a range of financial assistance programs to help eligible patients with the cost of treatment. However, the website does not provide any specific information on how the price of Keytruda may vary based on dosage or treatment duration.
The third source, an article from FiercePharma [3], discusses a recent FDA approval for a new therapy that combines Keytruda with other drugs to treat certain types of cancer. While the article mentions the cost of Keytruda, it does not provide any information on how the price may vary based on dosage or treatment duration.
Overall, it appears that the price of Keytruda can vary based on a number of factors, including insurance coverage and financial assistance programs. However, the sources provided do not offer specific information on how the price may vary based on dosage or treatment duration. Patients who are considering treatment with Keytruda should consult with their healthcare provider and insurance company to understand their specific costs and coverage options.
Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/KEYTRUDA
[2] https://www.keytruda.com/financial-support/
[3] https://www.fiercepharma.com/pharma/seagen-genmab-gun-for-merck-s-keytruda-accelerated-fda-nod-for-adc-therapy-tivdak-cervical